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Abstract 
Osteopontin (OPN) plays an important role in cancer progression, however its prognostic 
significance and its downstream factors are largely elusive. In this study, we have shown that 
expression of OPN was significantly higher in bladder cancer specimens with higher T-stage or 
tumor grades. In addition, a high level of OPN was significantly associated with poorer survival in 
two independent bladder cancer patient cohorts totaling 389 bladder cancer patients with available 
survival data. We further identified Matrix metallopeptidase 9 (MMP9) and S100 calcium-binding 
protein A8 (S100A8) were both downstream factors for OPN in bladder cancer specimens and 
bladder cancer cell lines. Expression of OPN was significantly positively associated with that of 
MMP9 and S100A8, while overexpression of OPN resulted in upregulation of MMP9 and S100A8, 
and knockdown of OPN showed consistent downregulation of MMP9 and S100A8 expression 
levels. Importantly, expression levels of both MMP9 and S100A8 were significantly associated with 
higher T-stage, higher tumor grade and a shorter survival time in the bladder cancer patients. 
Interestingly, OPN expression only predicted survival in MMP9-high, but not MMP9-low 
subgroups, and in S100A8-low but not S100A8-high subgroups. Our results suggest that OPN, 
MMP9 and S100A8 all play a significant role in bladder cancer progression and are potential 
prognostic markers and therapeutic targets in bladder cancer. The mechanistic link between these 
three genes and bladder cancer progression warrants further investigation. 
Key words: Osteopontin, MMP9, S100A8, bladder, prognosis. 
Introduction 
Bladder cancer is a major cause of cancer-related 
death worldwide, with about 380,000 new cases and 
150,000 deaths per year [1]. More than 90% of bladder 
cancers are transitional cell carcinoma (TCC), and 
around 5% and 2% remaining cases are squamous cell 
carcinoma and adenocarcinoma, respectively [2]. TCC 
can be further divided into muscle invasive or 
non-muscle invasive; with muscle invasive bladder 
cancer has a poorer prognosis and a 10-year survival 
rate of only 50% [2]. 
Osteopontin (OPN) is a phosphorylated 
sialoprotein in human encoded by highly conserved 
gene SPP1. OPN is expressed approximately as 
34-kDa protein, and its full-length form is of 60-kDa 
[3] and secreted by various cells and plays an 
important role in cellular processes related to cancer 
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development [4]. It has specific splice variants: 
OPN-a, OPN-b and OPN-c [5]. OPN-c has been 
known to be a strong prognosis marker in breast, 
ovarian, lung and colorectal cancer cells [5] and found 
expressed in bladder cancer cells [6]. Alteration in 
numerous malignant cells is reported to induce higher 
OPN expression compared to normal cells [7, 8]. The 
higher the OPN expression, more drastic effects are 
observed in cell adhesion, cell proliferation, migration 
and extracellular matrix (ECM) invasion rates through 
interacting with αvβ3 integrin that is present in a 
variety of cells. OPN exists as a soluble cytokinase and 
a constituent of ECM, which ECM has a distinctive 
composition - the type IV collagen [9, 10]. OPN is 
shown to promote chemoresistance [11], stem cell 
properties / phenotype [12], autophagy [13], 
angiogenesis [14], cell migration [15], cell invasion [16, 
17], metastasis via epithelial-mesenchymal transition 
[18, 19] and immunosuppression in metastatic niche 
[20] in different cancers. It is also a prognostic marker 
in human cancers [21] including breast cancer [22, 23], 
colorectal cancer [24], lung cancer [25, 26], head and 
neck squamous cell carcinoma [27], gastric cancer [28, 
29] and prostate cancer [30]. We have also previously 
shown that OPN promotes breast cancer progression 
[23], and have identified its upstream [31, 32] and 
downstream targets [33]. Nonetheless, little is known 
regarding the role of OPN in bladder cancer.  
Previously, Ang et al. demonstrated that OPN 
plasma levels were elevated in higher stage of bladder 
transitional cell carcinoma [34]. Zhao also showed that 
high OPN plasma level was related to the more 
aggressive phenotype of bladder cancer [35]. 
Interestingly, plasma OPN level has been used to 
predict the disease stage and reoccurrence incidents 
showing similar results with higher level of plasma 
OPN found to be significantly associated with both 
higher T-stage and lymph node invasion [36]. Further 
study also revealed that increased level of OPN 
mRNA was associated with both muscle invasiveness 
and advanced disease stage, however, with a limited 
number of specimens (n = 77), no statistically 
significant survival difference was found between 
OPN-high and OPN-low groups of patients [37]. 
Study of OPN in vitro also found that knockdown of 
OPN in human bladder cancer cells reduced its 
proliferation and migration [38]. These studies have 
demonstrated the importance of OPN in bladder 
cancer progression. Nevertheless, the downstream 
targets of OPN and the mechanisms of OPN-mediated 
bladder cancer progression are largely unknown, and 
the prognostic significance of mRNA expression of 
OPN in bladder cancer remains a question. In this 
study, we aimed to investigate the expression level of 
OPN and its prognostic value and identified potential 
downstream targets of OPN in bladder cancer. 
Results 
OPN overexpression in bladder cancer 
specimens 
In GSE13507 datasets, there were four different 
types of specimens, including normal, surrounding 
mucosa, bladder cancer, and recurrent tumor. An 
ANOVA analysis showed that OPN expression was 
significantly higher in bladder cancer compared to 
other specimens (p < 0.001, Figure 1). By post-hoc 
analysis, bladder cancer had a significantly higher 
level of OPN expression compared to surrounding 
mucosa (Games-Howell test, p < 0.001), suggesting 
that OPN may play an important role in early 
development of bladder cancer.  
 
 
Figure 1. The association between OPN expression and bladder 
cancer. A box plot showing the expression level of OPN in different bladder 
specimens. 
 
The association between OPN expression and 
clinicopathological parameters in bladder 
cancer 
The association between OPN expression and 
T-stage was tested in three independent bladder 
cancer cohorts. In GSE13507, OPN expression was 
significantly positively correlated with T-stage (r = 
0.238, p < 0.001; Figure 2A). Similar results were 
obtained in GSE32894 and GSE32548. In these two 
datasets, there were two probes for OPN and these 
two probes (ILMN_1651354 and ILMN_2374449) were 
tested independently. As shown in Figure 2B and 2C, 
OPN expression, as dictated by ILMN_1651354 and 
ILMN_2374449, was significantly positively 
correlated with T-stage, respectively, in GSE32894 (r = 
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0.402, p < 0.001 and r = 0.356, p < 0.001, respectively). 
As shown in Figure 2D and 2E, OPN expression was 
significantly positively correlated with T-stage in 
GSE32548 for the probe IDs of ILMN_1651354 (r = 
0.310, p < 0.001) and ILMN_2374449 (r = 0.335, p < 
0.001). 
 
 
Figure 2. The association between OPN expression and T-stage. (A) A box plot showing the expression level of OPN in bladder cancer with different stages 
in patient cohort GSE13507. Box plots showing the expression level of OPN based on the probe (B) ILMN_1651354 and (C) ILMN_2374449 in bladder cancer with 
different stages in bladder in patient cohort GSE32894. Box plots showing the expression level of OPN based on the probe (D) ILMN_1651354 and (E) 
ILMN_2374449 in bladder cancer with different stages in in bladder in patient cohort GSE32548. 
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The association between OPN expression and 
tumor grading was also tested in three independent 
bladder cancer cohorts. In GSE13507, OPN expression 
was significantly higher in tumors with a high 
histological grade compared to those with a low 
histological grade (p < 0.001; Figure 3A). Similarly, in 
GSE32894, OPN expression was significantly 
positively correlated with tumor grading for probe 
ILMN_1651354 (r = 0.298, p < 0.001; Figure 3B) and 
probe ILMN_2374449 (r = 0.265, p < 0.001; Figure 3C). 
In another cohort, GSE32548, OPN expression was 
also significantly positively correlated with tumor 
grading for probe ILMN_1651354 (r = 0.265, p = 0.002; 
Figure 3D) and (r = 0.286, p = 0.001; Figure 3E). 
 
 
Figure 3. The association between OPN expression and tumor grade. (A) A box plot showing the expression level of OPN in bladder cancer with different tumor 
grades in patient cohort GSE13507. Box plots showing the expression level of OPN based on the probe (B) ILMN_1651354 and (C) ILMN_2374449 in bladder cancer with 
different tumor grades in bladder in patient cohort GSE32894. Box plots showing the expression level of OPN based on the probe (D) ILMN_1651354 and (E) ILMN_2374449 
in bladder cancer with different tumor grades in in bladder in patient cohort GSE32548. 
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Figure 4. The association between OPN expression and survival. Kaplan-Meier analysis showing survival curves for patients whose tumor expressed a 
high-level (Green) and a low level (Blue) of OPN in bladder cancer patients for (A) cancer specific survival and (B) overall survival in GSE13507. Kaplan-Meier analysis 
showing survival curves for patients whose tumor expressed a high-level (Green) and a low level (Blue) of OPN in bladder cancer patients for overall survival based 
on (C) probe ILMN_1651354, (D) ILMN_2374449 and (E) combined OPN average in GSE32894. (F) Kaplan-Meier analysis showing survival curves for the combined 
bladder cancer patient cohort.  
 
The association between OPN expression and 
survival in bladder cancer patients 
The association between OPN expression and 
survival was tested in two independent bladder 
cancer cohorts in which survival data was available. 
In GSE13507, a high-level expression of OPN was 
significantly associated with a shorter disease specific 
survival time (p = 0.021; Figure 4A), while it was also 
significantly associated with a shorter overall survival 
time (p = 0.028; Figure 4B). Similarly, in GSE32894, a 
high-level expression of OPN was significantly 
associated with a shorter overall survival time for 
probe ILMN_1651354 (p = 0.008; Figure 4C), probe 
ILMN_2374449 (p = 0.017; Figure 4D) and the average 
of the two probes (p = 0.014; Figure 4E). When the 
data of the two cohorts were combined, patients 
whose tumors expressed OPN at a high-level had a 
mean survival time of 85.5 months (95% CI = 75.4 – 
95.7 months) and those patients whose tumors 
expressed OPN at a low level had a mean survival 
time of 107.1 (95% CI = 98.7 – 115.5). A high-level 
expression of OPN was significantly associated with a 
shorter overall survival time in these 389 bladder 
cancer patients (p = 0.001; Figure 4F). 
Identification of OPN co-expressing genes in 
bladder cancer 
By using 2-sample Welch’s T-test, several genes 
were found to be consistently and significantly 
differentially expressed in the two bladder cancer 
datasets, GSE13507 and GSE32894, and have been 
shown to have a link in published articles. Two 
metastasis-associated genes, S100A8 and MMP9, three 
cluster of differentiation genes, CD14, CD80 and 
CD163, and two oxygen pathway genes, MOX1 and 
NOX4, were found to be significantly higher in 
OPN-high tumors compared to OPN-low tumors. The 
correlation between the expression levels of these 
genes was analyzed by Spearman’s rank test, and we 
found that the expression levels of these genes were 
significantly correlated with that of OPN (Table 1). 
The expression levels of S100A8 and OPN have both 
been shown to be increased in stroma in prostate 
cancer with loss of JunB expression [39]. Knockdown 
of OPN in colon cancer suppressed the expression of 
MMP9 [40]. Since OPN is a metastasis-associated 
gene, the correlation between OPN and MMP9, and 
between OPN and S100A8 were investigated in vitro. 
We tested the expression levels of OPN, MMP9 and 
S100A8 in two high grade bladder cancer cell lines, 
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T24 and TCCSUP cells. Interestingly, TCCSUP cells 
expressed OPN (Figure 5A), MMP9 (Figure 5B) and 
S100A8 (Figure 5C) at a significantly higher level 
compared to T24 cells regardless of the availability of 
serum. The gene expression level of OPN was 
observed highest in serum-free and growth media of 
TCCSUP cells (grade IV), which was about 85.9-fold 
change, and lesser than one-fold for T24 cells. Since 
T24 cells expressed a low level of OPN, MMP9 and 
S100A8, this cell line was used to further study the 
association between these three genes via OPN 
overexpression. This is accomplished using a flag 
epitope tagged to the amplified OPN gene. 
Overexpression of OPN in T24 cells resulted in an 
increased mRNA expression of OPN (Figure 5D), 
MMP9 (Figure 5E) and S100A8 (Figure 5F). The 
results were confirmed in gene expression level with a 
fold change of 4.8 and 2.7 for S100A8 and MMP9 
respectively, and with western blot analysis. As 
shown in Figure 5G, overexpression of OPN resulted 
in an increase in OPN, MMP9 and S100A8 protein 
levels in T24 cells. The protein levels of S100A8 and 
MMP9 corresponded to the elevated OPN expression, 
and the intensity of S100A8 band was increased 
significantly, while MMP9 band demonstrated 
obvious clear band compared to the vector control. 
Additionally, we performed an siRNA transient 
transfection to knockdown the OPN in TCCSUP cell 
line and a decrease in MMP9 and S100A8 protein 
expression levels were observed respectively (Figure 
S1). These collective results clearly propose that 
MMP9 and S100A8 are the downstream targets of 
OPN-mediated metastasis.  
The associations between expression of MMP9 
and S100A8, and clinicopathological 
parameters in bladder cancer 
As shown in Figure 6A and 6B, a significant 
positive correlation was observed between MMP9 
expression and T-stage in two independent bladder 
cancer cohorts. Similarly, the expression levels of 
S100A8 was also significantly positively correlated 
with T-stage in these two bladder patient cohorts 
(Figure 6C and 6D). In addition, increased levels of 
expression of MMP9 (Figure 6E and 6F) and S100A8 
(Figure 6G and 6H) were observed in bladder cancer 
specimens with higher tumor grade in both cohorts. 
Our results suggest that both the expression levels of 
MMP9 and S100A8 are associated with a more 
aggressive phenotypes of bladder cancer.  
The associations between expression of MMP9 
and S100A8, and survival in bladder cancer 
We further investigated whether MMP9 and 
S100A8 are prognostic indicators in bladder cancer. In 
patients, whose bladder cancer had a low level of 
expression of MMP9 had a mean survival time of 102 
months (95% CI = 93 – 111 months) compared to those 
patients whose bladder cancer had a mean survival 
time of 95 months (95% CI = 86 – 105 months). As 
shown in Figure 7A, a high-level of MMP9 was 
significantly associated with a shorter survival time in 
bladder cancer patients (p = 0.016). Similarly, patients 
whose bladder cancer expressed a high-level of 
Table 1. GSE13507 Bladder cancer dataset (n = 165); Correlation of CD133 and other gene expressions 
 OPN S100A8 MMP9 CD14 CD80 CD163 HMOX1 NOX4 
Spearman's rho 
test 
OPN Correlation 
Coefficient 
1.000 0.394 0.475 0.440 0.366 0.550 0.432 0.278 
P value  <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
S100A8 Correlation 
Coefficient 
0.394 1.000 0.454 0.419 0.213 0.413 0.477 0.316 
P value <0.001  <0.001 <0.001 0.006 <0.001 <0.001 <0.001 
MMP9 Correlation 
Coefficient 
0.475 0.454 1.000 0.633 0.491 0.630 0.537 0.236 
P value <0.001 <0.001  <0.001 <0.001 <0.001 <0.001 0.002 
 CD14 Correlation 
Coefficient 
0.440 0.419 0.633 1.000 0.480 0.823 0.486 0.198 
P value <0.001 <0.001 <0.001  <0.001 <0.001 <0.001 0.011 
CD80 Correlation 
Coefficient 
0.366 0.213 0.491 0.480 1.000 0.463 0.351 0.161 
P value <0.001 0.006 <0.001 <0.001  <0.001 <0.001 0.039 
CD163 Correlation 
Coefficient 
0.550 0.413 0.630 0.823 0.463 1.000 0.596 0.134 
P value <0.001 <0.001 <0.001 <0.001 <0.001  <0.001 0.085 
HMOX1 Correlation 
Coefficient 
0.432 0.477 0.537 0.486 0.351 0.596 1.000 0.056 
P value <0.001 <0.001 <0.001 <0.001 <0.001 <0.001  0.477 
NOX4 Correlation 
Coefficient 
0.278 0.316 0.236 0.198 0.161 0.134 0.056 1.000 
P value.  <0.001 <0.001 0.002 0.011 0.039 0.085 0.477  
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S100A8 had a mean survival time of 84 months (75 – 
94 months), which was significantly shorter compared 
to those patients whose bladder cancer expressed a 
low level of S100A8, with a mean survival time of 108 
months (95% CI = 100 – 117 months, p < 0.001; Figure 
7B). We also investigated how these two genes 
interacted with OPN-survival association in these two 
bladder cancer patient cohorts. While the survival 
time was not significantly different between patients 
whose tumor expressed a low level of OPN vs. those 
with a high-level of OPN in the MMP9-low patient 
subgroup (Figure 7C), while in the MMP9-high 
subgroup, patients whose bladder cancer had a 
high-level of OPN expression had a significantly 
shorter survival time compared to those patients 
whose cancer had a low level of OPN-expression (p = 
0.037; Figure 7D). In contrast, OPN was significantly 
associated with survival only in bladder cancer 
patients whose cancer had a low level expression of 
S100A8 (p = 0.043; Figure 7E), but not in those with a 
high-level expression of S100A8 (Figure 7F).  
 
 
Figure 5. The analysis of expression levels of OPN, MMP9 and S100A8 in bladder cancer cell lines. Histograms showing qPCR analysis for (A) OPN, (B) 
MMP9 and (C) S100A8 in T24 and TCCSUP bladder cancer cell lines. Histograms showing qPCR analysis for (D) OPN, (E) MMP9 and (F) S100A8 in T24 cells 
overexpressing OPN and vector control and (G) western blot analysis for protein levels of OPN, MMP9, S100A8 and Actin in T24 cells overexpressing OPN 
(3xF-OPN) and vector control (3xFlag). n=9, **p<0.05 vs. control and is statistically analyzed with T-test. 
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Figure 6. The association between expression levels of MMP9 and S100A8, and clinicopathological parameters. Box plots showing the expression levels of 
MMP9 in bladder cancer specimens with different T-stage in patient cohort (A) GSE13507 and (B) GSE32894. Box plots showing the expression levels of S100A8 in bladder 
cancer specimens with different T-stage in patient cohort (C) GSE13507 and (D) GSE32894. Box plots showing the expression levels of MMP9 in bladder cancer specimens with 
different tumor grades in patient cohort (E) GSE13507 and (F) GSE32894. Box plots showing the expression levels of S100A8 in bladder cancer specimens with different tumor 
grades in patient cohort (G) GSE13507 and (H) GSE32894. 
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Figure 7. The association between MMP9, S100A8 and OPN with survival. Kaplan-Meier analysis showing survival curves for patients expressing different 
levels of (A) MMP9 and (B) S100A8 in the combined bladder cancer patient cohort. Kaplan-Meier analysis showing survival curves for patients expressing different 
levels of OPN in bladder cancer patients whose tumor expressed (C) a low level of MMP9, (D) a high-level of MMP9, (E) a low-evel of S100A8 and (F) a high-level of 
S100A8. 
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Discussion 
OPN has been shown to play an important role 
in disease progression in multiple types of cancer [5, 
6, 21]. The upregulated OPN level is shown to 
correlate with malignant grade and metastasis [5, 6, 
41]. One reason could be due to the OPN production 
by lymphocytes and macrophages although they are 
not expressed in circulating monocytes. These white 
blood cells are reported by Sodek and colleagues 
(2000) to induce OPN concentration in diseased 
tissues [42]. Furthermore, those compiled GEO 
datasets have revealed and supported co-expressing 
genes upregulated along with higher OPN expression 
in advanced bladder cancer. Subsequently, we 
decided to further study MMP9 and S100A8 to 
establish the correlation between OPN and these 
co-expressed genes. MMP9 has been reported to be 
co-expressed with OPN [43, 44], while S100A8 with 
OPN in several publications [39, 45]. Our results 
showed that the upregulation of MMP9 and S100A8 
gene and protein levels correspond to the OPN 
overexpression and downregulation of these 
genes/proteins with knockdown of OPN. Matrix 
metalloproteinase, (MMP) family is an important 
ECM-degrading proteinase [7, 46, 47] and one of 
metalloproteinase activities is to facilitate cell 
migration [48]. ECM, however, consists a barrier that 
prevents migration. Type IV collagen, a distinctive 
component of ECM and is degraded by the enzyme 
encoded by MMP9 gene because it consists of a 
collagen binding domain which is located between 
the catalytic region and C-terminal hemopexin 
domain [46]. Therefore, breaking down the collagen 
barrier is necessary for migration with ECM 
degradation process. MMP claims to selectively 
degrade certain components of ECM and 
subsequently releases growth factors that exist within 
the ECM [46]. Stawarski et al. reported that 
intercellular intergrin signaling pathway is activated 
when the ECM protein is cleaved [49]. OPN molecule 
can be cleaved by several MMPs, including MMP9 
resulting in an N-terminal section consists of the RGD 
sequence [50]. The highly conserved RGD domain of 
OPN interacts with several integrins, such as αvβ3, 
and this interaction (OPN/αvβ3) mediates cell 
adhesion and migration [42]. Lenga et al. found that 
OPN-/- fibroblasts have low attachment to collagen 
gels and impair the formation of super mature focal 
adhesion which cause weak adhesions to ECM [51]. 
This depicts the importance of OPN in affecting and 
changing the cancer phenotypic characteristics.  
MMP9 has been reported to be involved in the 
pathogenesis of bladder cancer and other cancers 
when it is upregulated [47, 52]. Both pro-MMP9 and 
its active form have a PEX-domain that either docks 
or/and form heterodimeratization with the surface 
receptor, CD44 in the OPN molecule of T24 cells. This 
docking is predicted to eventually lead to cell survival 
via Lyn kinase activation and heterodimerization 
binding that causes subsequent phosphorlysation of 
kinase effectors, effect upon EGFR activation. MMP9 
active form supports cell survival and migration, thus 
this suggests why MMP9 and OPN expression levels 
are higher in advanced invasive cancer cells, e.g., 
TCCSUP compared to T24 [46]. Therefore, 
upregulation of OPN and its co-expressing gene, 
MMP9 play an important role in cancer cell migratory 
and adhesive properties. 
In bladder cancer, overexpression of OPN is 
correlated with cancer-specific survival of upper 
urinary tract urothelial carcinoma with limited 
number specimens [53]. In the present study, we 
found that a high-level expression of OPN mRNA 
was significantly associated with T-stage and tumor 
grade, and most importantly, it was consistently 
associated with shorter disease-specific and overall 
survival in two independent bladder cancer patient 
cohorts. This finding is consistent with the study 
published in 2017 by Hussain et al [41] which revealed 
that OPN was significantly overexpressed in invasive 
bladder cancer compared to healthy tissue. 
Importantly, we identified two metastasis-related 
genes, MMP9 and S100A8, that could potentially be 
the downstream targets of OPN promoting bladder 
cancer progression. These two genes were 
upregulated by OPN overexpression in bladder 
cancer cell lines, and a high-level expression of these 
two genes, individually, was also associated with 
higher T-stage, tumor grade, and poorer survival. 
Meanwhile, we investigated the siRNA knockdown of 
OPN gene in TCCSUP cell line, we found that the 
downregulation of OPN reduced the expression of 
MMP9 and S100A8. Wu et al. reported that 
knockdown of OPN has inhibited the MMP9 
expression [40] and Lim et al. observed that MMP9 is 
downregulated in S100A8 knockdown cancer cells 
[54]. Our results support and further extend previous 
publication studies. Our results suggest that OPN 
could be an important prognostic marker and a 
therapeutic target in bladder cancer, and that MMP9 
and S100A8 could be potential downstream targets for 
OPN-mediated metastasis.  
In general, the MMP9 expression level is notably 
lower than OPN expression in the cell basal level 
because MMP9 is secreted in its latent form and 
generated upon activation. The OPN/αvβ3 signaling is 
known to control CD44 surface expression, MMP9 
stimulation, and migration in osteoclast [42, 55]. We 
hypothesized that OPN/αvβ3 signaling would cause 
similar effect in T24 cells. Phillip et al. reported that 
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OPN does stimulate tumor growth, cell migration and 
invasion; it also further activates the matrix 
metalloproteinases [7]. OPN/αvβ3 signaling can 
potentiate MMP production by activating the 
downstream kinase effector, the FAK in addition to 
the ERK pathway. This pathway not only promotes 
Fos expression via phosphorylation, which further 
stimulates MMPs assembly, but also directly activate 
pro-MMP2 [42]. MMP9 (82 kDa) is secreted in its 
proenzyme form, pro-MMP9 (92 kDa).  
The relationship between OPN and MMP9 has 
been demonstrated in aortic mesenchymal cells, in 
which OPN treatment of vascular smooth muscle cells 
enhanced pro-MMP9 activity [43], and MMP9 was 
upregulated by OPN in cardiac and skeletal muscle 
resulting in cardiac abnormalities [56]. In gastric 
cancer, OPN also promotes metastasis via MMP9 
activation [57] while in colon cancer cells, knockdown 
of OPN resulted in reduced expression of MMP9 [44]. 
MMP9 activity has been shown to be higher in 
invasive bladder cancer compared to normal control 
[58]. Knockdown of MMP9 by microRNAs in bladder 
cancer cells also resulted in decreased cell invasion 
[59]. However, the prognostic significance of MMP9 
has not yet been fully elucidated. In the present study, 
we have shown that increased expression of MMP9 
was correlated with higher T-stage, tumor grade and 
a shorter survival in bladder cancer. Our results 
suggest that MMP9 may be an important prognostic 
marker for bladder cancer. Interestingly, since 
OPN-survival association was only observed in 
MMP9-high patient subgroup, OPN-mediated 
bladder cancer progression may be dependent on the 
presence of high-level of MMP9. 
Some of the intercellular functions that are 
affected when some S100 proteins undergo 
conformational changes are regulation of calcium 
homeostasis, cell growth and migration, cell cycle and 
phosphorylation [60]. Any alterations during cell 
development could promote potential oncogenesis 
progression. Little is known about the relationship 
between OPN and S100A8. A highly metastatic colon 
cancer cell line expressed elevated levels of OPN, 
MMP9 and S100A8 [45], while in a prostate cancer 
model, the tumor stroma was altered with increased 
expression of OPN and S100A8 [39]. S100A8 was 
demonstrated to have higher expression in bladder 
cancer compared to normal bladder tissue [61], and 
S100A8 alone was shown to be a prognostic marker 
[62] while an S100A8 gene signature was shown to be 
a strong predictor of disease progression for bladder 
cancer [63]. In line with these results, our results 
showed that a high-level expression of S100A8 was 
associated with higher T-stage and tumor grade, and 
a shorter survival time.  
From our results, we have verified that the OPN 
overexpression lead to an increase in MMP9 and 
S100A8 expression, while the knockdown of OPN 
showed converse effect in MMP9 and S100A8 
expression levels. Based on these results, we evidently 
proposed that MMP9 and S100A8 are downstream of 
OPN. The expression levels of these three genes were 
positively correlated in human bladder cancer 
specimens, the mechanism of OPN-mediated 
upregulation of MMP9 and S100A8 was not 
investigated in the present study. Although we found 
that OPN, MMP9 and S100A8 are all prognostic 
markers for bladder cancer patients, we have not fully 
elucidated how the interactions of these three genes 
promote bladder cancer progression in this study. The 
establishment of mechanistic insight on the 
interactions of these three genes with bladder cancer 
progression will lead to a better understanding of 
how OPN promotes bladder cancer progression. 
Nonetheless, our results have demonstrated that OPN 
may regulate MMP9 and S100A8 to promote bladder 
cancer progression, and the expression levels of OPN 
may be a prognostic marker and therapeutic target for 
human bladder cancer.  
In conclusion, taken together, OPN, MMP9 and 
S100A8 all play significant roles in bladder cancer 
progression and are potential prognostic markers and 
therapeutic targets in bladder cancer. 
Materials & Methods 
Cell lines and reagents 
Two poorly differentiated bladder cancer cell 
lines T24 and TCCSUP were purchased from ATCC. 
These cell lines were grown in cell culture media (T24 
in McCoy's 5a medium modified, Gibco: 16600082; 
TCCSUP in Minimum essential medium Gibco: 
11095080 and 1 mM sodium pyruvate) added with 
10% fetal bovine serum, 1% penicillin/streptomycin. 
RNA purification and cDNA preparation  
Gene expressions were induced in all bladder 
cell lines by culturing in 10% serum and another batch 
following a 24-h duration of serum starvation prior 
RNA purification (RNeasy Mini Kit, 74106), followed 
by converting 1 µg of samples to synthesized cDNA 
using a thermal cycler (C1000 Touch, Bio Rad) (High 
Capacity cDNA Reverse Transcription Kit, 4368813, 
Applied Biosystems).  
qPCR validation  
The amounts of three target genes such as OPN, 
MMP9 and S100A8 cDNA present in the bladder cell 
lines were quantified by quantitative PCR using 
TaqMan probes using GAPDH as an endogenous 
control. Equivalent amount of cDNA was subjected to 
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quantitative PCR detection. The final concentration of 
the 1X master mix (Taqman Universal PCR Master 
Mix, #4304437) followed by respective probes (SPP1: 
Hs00959010_m1; MMP9: Hs00234579_m1; S100A8: 
Hs00374264_g1; GAPDH: Hs02758991_g1; Life 
Technologies). The parameters were set using the 
Bio-Rad CFX Manager where FAM scan mode 
detection with 40 cycles were selected. Data 
normalization was accomplished using the GAPDH 
and normalized values were subjected to a 2-ΔΔCt 
formula to quantify the fold change. Individual CT 
and intrasample variable values, the mean ± SD were 
calculated from the generated results.  
Total protein quantification and western blot 
analysis  
The cell line samples were homogenized with 
ice-cold RIPA lysis buffer that was added with 
protease inhibitor (Complete EDTA-free, #10634200, 
Roche) and phosphatase inhibitor (PhosSTOP, 
#04906837001, Roche) and centrifuged at 20,000 x g 
for 30 minutes at 4°C. Supernatants were collected 
and kept in -80°C. Bradford method was used to 
quantify the protein concentration required for 
western blot sample loading (Pierce BCA Protein 
Assay Kit, #23225). All samples were dissolved in 1X 
LDS sample buffer and 1X reducing agent (Life 
Technologies) and heated for 5 minutes at 95°C. An 
equal concentration of protein was electrophoresed 
and separated in NuPage 4-12% Bis-Tris gel 
(Invitrogen, #NP0322) and transferred to a 0.2 um 
nitrocellulose membrane (#IB301032) using iBlot 
(Invitrogen). Blocking was carried out in 5% bovine 
serum albumin, 0.1% Tween 20 in PBS for non-specific 
binding for an hour at room temperature. The 
membranes were incubated overnight at 4°C with 
mouse monoclonal primary antibodies: OPN, 
LFMb-14 (1:200, sc-73631, Santa Cruz biotechnology); 
anti-flag (1:2000, F1804, Sigma), MMP9 2c3, (1:500, 
sc-21733, Santa Cruz Biotechnology), Anti-HS100A8 
(1:500, MAB4570, R&D Systems,) and normalized 
with actin, C4 (1:5000, sc-47778, Santa Cruz 
Biotechnology). They were washed and incubated for 
60 minutes at room temperature with secondary 
antibody, goat anti-mouse (1:5000, HRP, sc-2055, 
Santa Cruz Biotechnology). The membrane was 
visualized by chemiluminescent HRP substrate 
reagent (1:1) (Immobilon Western, WBKLS0500, 
Millipore) using ChemiDoc MP Imaging System (Bio 
Rad).  
Molecular cloning and gene transient 
transfection  
OPN-c gene of pcDNA3-OPN-V5 was a gift from 
Steven Johnson (Addgene plasmid # 11617). It was 
amplified by Phusion HF DNA polymerase (M0530L) 
and purified by the QIAquick PCR Purification Kit 
(#28106) and QIA gel Extraction kit (#28706). The PCR 
product was cut with NEB CutSmart and ligated 
overnight at 16°C to p3XFLAG-CMV™-7.1 expression 
vector (E7533 SIGMA). Transformation was 
performed with competent E. coli cells (One Shot 
Top10, #C404003, Thermofisher). The overexpression 
gene transient transfection was carried out with 
Lipofectamine 3000 reagent (Invitrogen, CA, USA), 
while transient knockdown using Mission® esiRNA 
(EHU018231 SIGMA) with Lipofectamine 2000 
following the manufacturer’s protocol. The cell was 
seeded to be 60-70% confluent prior transfection. The 
ratio of plasmid DNA/Lipofectamine 3000 was 
selected as 2.5 µg / 3.75 µl for the OPN 
overexpression transfection and siRNA/Lipo-
fectamine 2000 for transient knockdown was used at 
1200 ng / 4 µl process (5× 105 cells in 3 ml complete 
culture medium per well of a 6-well plate). The cell 
was post-transfected for 48 hours at 37°C, then the 
transfection efficacy was determined by qPCR 
quantification and western blot analysis.  
GEO Dataset computational analysis -- 
Extraction of clinical and microarray gene 
expression data from bladder cancer patient 
datasets  
Two bladder cancer patient datasets, GSE13507 
(n = 256) [64] and GSE32894 (n = 308) [65] GSE32548 
(n = 131) [66] were identified from Gene Expression 
Omnibus database based on the following search 
criteria: 1.) bladder or urothelial cancer, 2.) available 
information on clinicopathological parameters, 3.) 
available information on gene expressions and 4.) 
with sample size more than 100. The GEO website has 
standardized URLs for its individual datasets, e.g. the 
overall summary information about the microarray 
dataset GSE13507 can be accessed at 
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?a
cc=GSE13507. These two datasets were publicly 
available. For each GEO data series, links are 
provided at the bottom of the page to the Series 
Matrix File(s), which contain the expression values for 
each gene (probeset) and each microarray. The URLs 
to the Series Matrix File(s) are also standardized. For 
GSE13507, the URL was http://ftp.ncbi.nlm.nih.gov/ 
pub/geo/DATA/SeriesMatrix/GSE13507. The files 
in gzip format were then unzipped to the 
tab-delimited text format, which contain detailed 
information for statistical analysis. R scripting was 
used to extract the expression values of a small 
number of genes (probesets) of interest and the 
clinical data from the data matrixes downloaded from 
GEO.  
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Correlations of gene expression levels and 
clinical data 
The associations between expression levels of 
genes were analyzed by Spearman’s rank test. 
Expression levels were further divided into high and 
low levels using the median expression level as the 
cut-off point for Kaplan-Meier survival analysis. 
Results were compared by log-rank test. These 
statistical analyses were performed using SPSS 19.0 
and a p-value of < 0.05 was considered as significant. 
Identification of OPN co-expressing genes 
Patients were stratified into two groups based on 
the expression levels of OPN as described above. The 
gene expression patterns of patients in OPN-low 
subgroup and those in the OPN-high subgroup 
(whose survival was significantly poorer) were 
compared. Probesets that were differentially 
expressed between these two subgroups were 
identified by 2-sample Welch’s T-test. This test was 
used to avoid the type I error due to unequal 
variances of the values of probesets between 
subgroups. Briefly, a Welch’s t test was applied to 
each probeset corresponding to a certain gene in the 
data matrix using our own Java application MyStats. 
P values and the differential expression in fold 
changes for all the probesets were generated as 
tab-delimited worksheets of Excel for further analysis.  
Identification of therapeutic targets for 
bladder cancer patients overexpressing OPN 
Patients who had their tumors expressing a 
high-level of OPN were stratified into two groups 
based on their survival status (alive or deceased). 
Differential expressions of different probesets 
between patients in the OPN high-alive subgroup and 
those in the OPN high-deceased subgroup were 
identified as described above. 
Statistical analysis 
Statistical analysis between gene was performed 
using the R-Script and Levene’s Test for homogeneity 
and followed by T-test in primary qPCR experiment. 
Other data are expressed as means ± SD. Mean 
between groups were compared using a T-test and 
difference between multiple group were analyzed by 
1-way ANOVA in Prism 6.0. In all analysis, P < 0.05 
was considered statistically significant.  
Abbreviations 
OPN: Osteopontin; MMP9: Matrix metallope-
ptidase 9; S100A8: S100 calcium-binding protein A8; 
TCC: Transitional cell carcinoma; ECM: extracellular 
matrix; FAK: Focal adhesion kinase.  
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